(Q39712345)

14 September 2017

Drugs for Neglected Diseases initiative model of drug development for neglected diseases: current status and future challenges (English)

1 reference

14 September 2017

1

Jean-Robert Ioset

1 reference

14 September 2017

Shing Chang

2

1 reference

14 September 2017

1 September 2011

1 reference

Future Medicinal Chemistry

14 September 2017

1 reference

14 September 2017

3

1 reference

14 September 2017

1361-1371

1 reference

14 September 2017

11

1 reference

Neglected tropical diseases

14 September 2017

1 reference

https://api.crossref.org/works/10.4155%2FFMC.11.102

Neglected tropical diseases in sub-saharan Africa: review of their prevalence, distribution, and disease burden

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.11.102

"Manifesto" for advancing the control and elimination of neglected tropical diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.11.102

Socioeconomic aspects of neglected tropical diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.11.102

Measuring the burden of neglected tropical diseases: the global burden of disease framework

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.11.102

Drug development for neglected diseases: a deficient market and a public-health policy failure

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.11.102

Global framework on essential health R&D.

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.11.102

New drugs for neglected diseases: from pipeline to patients

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.11.102

Virtual drug discovery and development for neglected diseases through public-private partnerships

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.11.102

Public-private partnership: from there to here

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.11.102

Benzoxaboroles: a new class of potential drugs for human African trypanosomiasis

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.11.102

N-myristoyltransferase inhibitors as new leads to treat sleeping sickness

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.11.102

Trypanothione reductase high-throughput screening campaign identifies novel classes of inhibitors with antiparasitic activity

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.11.102

Chemical validation of trypanothione synthetase: a potential drug target for human trypanosomiasis

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.11.102

Development of an Alamar Blue viability assay in 384-well format for high throughput whole cell screening of Trypanosoma brucei brucei bloodstream form strain 427.

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.11.102

Fexinidazole--a new oral nitroimidazole drug candidate entering clinical development for the treatment of sleeping sickness

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.11.102

The use of the 2 substituted 5-nitroimidazole, Fexinidazole (Hoe 239) in the treatment of chronic T. brucei infections in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.11.102

21 January 2018

Identifiers

DOI

10.4155/FMC.11.102

1 reference

14 September 2017

1 reference

PubMed ID

21879842